While BRD4 inhibitors are still in clinical trials; Vorinostat[24] is an FDA approved anti‐cancer drug, which did not cause toxicity in microHOs nor did it cause hepatitis or clinically apparent liver injury in treated subjects.[41] Vorinostat is being considered as a treatment for other types of cancers,[42] but it had not previously been considered for treatment of liver fibrosis. This evidence concerns the gene BRD4 and Hepatic fibrosis.